EP Patent

EP0475148A1 — Pravastatin alone or in combination with a fibric acid derivative for preventing onset of or treating type III hyperlipoproteinemia

Assigned to ER Squibb and Sons LLC · Expires 1992-03-18 · 34y expired

What this patent protects

The use of pravastatin alone or in combination with a fibric acid derivative such as fenofibrate, gemfibrozil or bezafibrate for the preparation of a pharmaceutical composition useful in preventing or treating Type III hyperlipoproteinemia is described.

USPTO Abstract

The use of pravastatin alone or in combination with a fibric acid derivative such as fenofibrate, gemfibrozil or bezafibrate for the preparation of a pharmaceutical composition useful in preventing or treating Type III hyperlipoproteinemia is described.

Drugs covered by this patent

Patent Metadata

Patent number
EP0475148A1
Jurisdiction
EP
Classification
—
Expires
1992-03-18
Drug substance claim
No
Drug product claim
No
Assignee
ER Squibb and Sons LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.